Sinopsis
A selection of the best interviews conducted by physician leaders and recorded at cardiology conferences around the globe.
Episodios
-
Episode 179: The SODIUM-HF Study
12/07/2023 Duración: 10minJustin Ezekowitz and C. Michael Gibson look at a sodium-reducing dietary intervention and its effects on patients with HF.
-
Episode 178: The COMPLETE Trial
05/07/2023 Duración: 07minShamir Mehta and C. Michael Gibson discuss how complete revascularization affects angina-related quality of life in patients with STEMI.
-
Episode 177: The EDIT-CMD Trial
14/06/2023 Duración: 10minTijn Jansen, Suzette Elias-Smale, and C. Michael Gibson discuss whether diltiazem improves coronary vasomotor dysfunction in patients with angina and nonobstructive coronary artery disease.
-
Episode 176: The IVVE Trial
24/05/2023 Duración: 07minMark Loeb and C. Michael Gibson discuss whether the influenza vaccine can reduce adverse vascular events among patients with HF.
-
Episode 175: The METEORIC-HF Trial
17/05/2023 Duración: 08minGregory Lewis and C. Michael Gibson discuss how omecamtiv mecarbil affects exercise tolerance in patients with chronic HFrEF.
-
Episode 174: The DIAMOND Trial
03/05/2023 Duración: 07minJaved Butler and C. Michael Gibson discuss using patiromer to manage hyperkalemia in patients with HFrEF who are taking RAAS inhibitors.
-
Episode 173: MAVA-LTE: The EXPLORER-LTE Cohort
19/04/2023 Duración: 08minFlorian Rader and C. Michael Gibson look at cumulative outcomes for patients with obstructive hypertrophic cardiomyopathy treated with mavacamten.
-
Episode 172:The PACIFIC-AF Study
05/04/2023 Duración: 07minManesh Patel and C. Michael Gibson discuss the results of a phase II trial comparing the safety profiles of asundexian versus apixaban in patients with atrial fibrillation.
-
Episode 171: The PROTECT Trial
22/03/2023 Duración: 07minDaniel Sessler and C. Michael Gibson compare myocardial injury rates following mild hypothermia versus aggressive warming during noncardiac surgery.
-
Episode 170: The ADAPT-TAVR Trial
08/03/2023 Duración: 14minDuk-Woo Park and C. Michael Gibson discuss edoxaban vs dual antiplatelet therapy for valve thrombosis and cerebral thromboembolism after TAVI.
-
Episode 169: The FLAVOUR Trial
01/03/2023 Duración: 16minBon-Kwon Koo and C. Michael Gibson compare the efficacy of FFR-guided and IV ultrasound-guided PCI for coronary artery stenosis.
-
Episode 168: The GIPS-IV Study
08/02/2023 Duración: 08minMarie-Sophie de Koning and C. Michael Gibson discuss whether the use of sodium thiosulfate after STEMI helps preserve cardiac function.
-
Episode 167: The Spyral HTN-ON MED Pilot Study
01/02/2023 Duración: 05minFelix Mahfoud and C. Michael Gibson examine the efficacy of renal denervation for long-term BP reduction in patients taking antihypertensive medication.
-
Episode 166: Chronic Kidney Disease In CANTOS
11/01/2023 Duración: 07minPaul Ridker and C. Michael Gibson discuss a secondary analysis from CANTOS looking at residual inflammatory and cholesterol risks based on chronic kidney disease status.
-
Episode 165: The STAR-T/D Trial
04/01/2023 Duración: 04minMichael Mack and C. Michael Gibson discuss a novel method for extracting antithrombotics from the blood during CABG.
-
Episode 164: The LOOP Study for AF Screening
14/12/2022 Duración: 16minC. Michael Gibson and Jesper Hastrup Svendsen discuss the use of implantable loop recorders to prevent stroke in AF.
-
Episode 163: The ENVISAGE-TAVI AF Trial
07/12/2022 Duración: 07minC. Michael Gibson and George Dangas discuss edoxaban vs vitamin K antagonists after TAVI in patients with atrial fibrillation.
-
Episode 162: The FIGARO-DKD Trial
23/11/2022 Duración: 07minEpisode 162: The FIGARO-DKD Trial by TCTMD
-
Episode 161: AMULET-IDE: One-Year Outcomes
09/11/2022 Duración: 06minC. Michael Gibson and Dhanunjaya Lakkireddy discuss device success and thrombus risk in Amulet versus Watchman for LAA closure.
-
Episode 160: Shock Classification Gets an Update
02/11/2022 Duración: 04minC. Michael Gibson and Timothy Henry discuss key updates to the SCAI SHOCK classifications.